boehringer ingelheim glp-1 π¨ Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today π SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks βοΈ 16.6% weight loss ( Boehringer dual-acting obesity shot hits
Description
All follow-up appointments may be completed virtually if preferred
Sun Y, Bennett A
GLP-1 is a naturally occurring hormone in the body that helps regulate blood sugar levels and appetite, which can be stimulated by injectable drugs such as Ozempic and Mounjaro
Weeks 9 to 12: 10 mg to 7.5 mg
Document these patterns to discuss with your healthcare provider
